{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.427","value":"38.36"},{"groupId":"OG001","spread":"8.912","value":"38.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.697","value":"40.14"},{"groupId":"OG001","spread":"14.249","value":"36.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"title":"Cycle 3 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants with primary cutaneous anaplastic large cell lymphoma (pcALCL) received brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).","id":"OG000","title":"pcALCL: Brentuximab Vedotin"},{"description":"Participants with mycosis fungoides (MF) received brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).","id":"OG001","title":"MF: Brentuximab Vedotin 1.8 mg/kg"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic (PK) population included participants with sufficient dose and PK data to reliably estimate PK parameters as determined by a clinical pharmacologist. Here 'Number analyzed' is the number of participants with evaluable data at the specified time-point.","reportingStatus":"POSTED","timeFrame":"Day 1 pre-dose and 30 minutes after infusion in Cycles 1 and 3","title":"Cmax: Maximum Observed Concentration for Brentuximab Vedotin","type":"SECONDARY","unitOfMeasure":"ug/mL"}